SC&H Financial Advisors Inc. Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW)

SC&H Financial Advisors Inc. lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 26.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,462 shares of the medical research company’s stock after selling 1,260 shares during the period. SC&H Financial Advisors Inc.’s holdings in Edwards Lifesciences were worth $256,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the fourth quarter worth about $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at about $32,000. Avior Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Finally, JFS Wealth Advisors LLC grew its position in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,000 shares of company stock worth $547,430 in the last three months. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Down 0.9 %

Edwards Lifesciences stock opened at $70.38 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business’s 50-day moving average price is $72.47 and its 200 day moving average price is $69.55. The firm has a market cap of $41.51 billion, a price-to-earnings ratio of 10.16, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of analyst reports. Truist Financial reissued a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Barclays raised their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a report on Thursday, January 16th. Finally, Morgan Stanley restated an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.